LabCorp and CareDx have officially pulled the plug on a previously announced agreement to develop a lupus flare predictor test after completing the first phase of their collaboration.
Tandem Diabetes Care, the maker of the t:slim insulin pump, has partnered with open-source software provider Tidepool. The deal is expected to better enable diabetes patients using the pump to download and access data from their device.
Illumina is lending a hand to Ebola diagnostic efforts, teaming up with U.S. government officials and researchers at the Broad Institute to help scientists in West Africa track the virus and develop new tools to prevent its spread.
Flowonix, maker of the implantable Prometra infusion pump for chronic pain patients, announced that it has raised $40 million in debt and equity financing led by private equity fund Élevage Capital Management.
Medical marijuana company CannScience Innovations entered into a nonbinding agreement to license Generex Biotechnology's RapidMist device for the buccal delivery of its developmental stage medical marijuana products.
Coming off a huge third quarter for revenue growth, genomic sequencing outfit Illumina this week inked a deal with Sequenta to commercialize a diagnostics kit that detects a condition associated with cancer remission.
Medtronic's fastest growing business is in diabetes, which gained 10% to $430 million in the most recent quarter over a year ago. Now the medical device giant is looking to expand beyond its dominance in Type 1 diabetes that is based on the success of its insulin pump MiniMed. During an earnings call, Medtronic disclosed that it reorganized its diabetes group last quarter.
Clovis Oncology has signed a deal to test whether its lead drug can make a difference in lung cancer when paired with GlaxoSmithKline's melanoma treatment Mekinist.
Dialysis provider DaVita HealthCare Partners has partnered with Medtronic for a pilot program to study cardiac arrhythmias in end-stage renal disease patients receiving dialysis. It will use the tiny implantable cardiac monitor, Linq, which Medtronic launched early this year.
Boehringer Ingelheim is working with managed care giant WellPoint in an effort to use real-world data to inform the development of new treatments of atrial fibrillation, keeping up with a sweeping trend in cardiovascular R&D.